Results from the Phase 3 FIGHT-302 trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, demonstrate that pemigatinib (Pemazyre®) significantly improves progression-free survival (PFS) over standard gemcitabine and cisplatin chemotherapy in the first-line treatment of patients with FGFR2 fusion- or rearrangement-positive cholangiocarcinoma. The trial also demonstrated substantially higher objective response rates and more durable responses with pemigatinib, supporting its potential as a biomarker-driven frontline treatment strategy. These findings represent a potentially practice-changing advance in the precision oncology management of this rare and lethal bile duct cancer.

Clinical Takeaway

In the largest randomized Phase 3 trial conducted in the first-line FGFR2-positive cholangiocarcinoma setting, pemigatinib reduced the risk of disease progression or death by 42%, achieved an objective response rate of 47% versus 15% with chemotherapy, and more than doubled median duration of response compared with gemcitabine/cisplatin chemotherapy. These data reinforce the clinical value of routine molecular profiling at diagnosis and support a potential shift toward biomarker-driven targeted therapy in the frontline setting for this genetically defined patient population.

Drug Profile & Mechanism

  • Drug name: Pemigatinib (Pemazyre®)
  • Developer: Incyte Corporation
  • Mechanism: Selective inhibitor of fibroblast growth factor receptors (FGFR) 1, 2, and 3, targeting oncogenic signaling driven by FGFR2 gene fusions or rearrangements
  • Regulatory status: Granted FDA accelerated approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement — the first targeted therapy approved in this indication; first-line use remains investigational and not yet FDA-approved

Target Population

  • Cancer type: Cholangiocarcinoma (bile duct cancer), specifically intrahepatic cholangiocarcinoma
  • Biomarker eligibility: Confirmed FGFR2 gene fusion or rearrangement
  • Prevalence of targetable alteration: Approximately 6%–10% of patients with intrahepatic cholangiocarcinoma harbor FGFR2 fusions or rearrangements
  • Treatment setting: Previously untreated (first-line), unresectable locally advanced or metastatic disease

Study Design

  • Trial name: FIGHT-302 (NCT03656536)
  • Phase: Global, randomized, Phase 3 trial
  • Comparator: Gemcitabine + cisplatin (Gem/Cis), the established standard-of-care chemotherapy regimen for advanced biliary tract cancer
  • Significance: Largest randomized Phase 3 trial conducted in the first-line FGFR2 fusion- or rearrangement-positive cholangiocarcinoma population
  • Crossover design: Patients who progressed on Gem/Cis were permitted to cross over to receive second-line pemigatinib; 42 patients crossed over
  • Enrollment: 4,563 patients were prescreened, 196 were screened, and 167 were randomized (83 pemigatinib; 84 chemotherapy)
  • Study status: The trial closed early because the standard of care changed during study conduct

Efficacy Outcomes

  • Progression-free survival (primary endpoint):
    • Pemigatinib: 8.3 months
    • Gemcitabine/cisplatin: 6.8 months
    • Hazard ratio (HR): 0.58 (95% CI, 0.39-0.87; nominal P = 0.0078), representing a 42% reduction in the risk of disease progression or death.
  • Objective response rate (ORR):
    • Pemigatinib: 47%
    • Gemcitabine/cisplatin: 15%
    • More than threefold higher ORR with pemigatinib
  • Median duration of response (DoR):
    • Pemigatinib: 14.2 months
    • Gemcitabine/cisplatin: 6.3 months
    • Represents a more than twofold improvement in duration of response with pemigatinib
  • Crossover cohort PFS:
    • Estimated median PFS among 42 patients who crossed over to pemigatinib after Gem/Cis: 8.1 months
    • Results are consistent with efficacy data from FIGHT-202, supporting pemigatinib’s activity following chemotherapy progression
  • Overall Survival (OS):
    • Pemigatinib: 24.4 months
    • Gemcitabine/cisplatin: 25.0 months
    • Median OS was similar between treatment groups at the time of analysis (24.4 vs 25.0 months). The permitted crossover to second-line pemigatinib should be considered when interpreting these results.

Safety

  • No new safety signals were identified
  • The safety profile of pemigatinib was consistent with its previously established safety profile

Expert Perspectives

Tanios S. Bekaii-Saab, MD, lead investigator, David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I at Mayo Clinic College of Medicine and Science and Division Chair of Hematology/Medical Oncology at Mayo Clinic in Phoenix, stated: “For patients with advanced bile duct cancer that have FGFR2 fusions or rearrangements, pemigatinib helped keep the cancer under control longer and shrank tumors more often than standard chemotherapy. These results suggest that pemigatinib may offer an effective first-line treatment option for this group of patients and represent an important step toward more personalized care.”

Arndt Vogel, MD, PhD, investigator and Professor and Clinician Scientist at the University of Toronto and University Health Network, added: “The FIGHT-302 study confirms the high efficacy of FGFR2-targeted therapy in FGFR2 fusion-positive cholangiocarcinoma and further supports its use as a standard treatment option. The magnitude of benefit also suggests that FGFR inhibition may be a valuable alternative for selected patients who cannot tolerate or wish to avoid chemotherapy in the first line. In addition, the high response rates raise the possibility of downstaging patients with borderline resectable disease. Overall, the results highlight the importance of routine molecular testing for FGFR2 alterations as early as possible.”

Key Clinical Implications

✔ Pemigatinib demonstrated statistically significant improvements in PFS, ORR, and DoR compared with gemcitabine/cisplatin, representing a potential paradigm shift for FGFR2 fusion- or rearrangement-positive cholangiocarcinoma management.

✔ Routine, early molecular testing for FGFR2 fusions or rearrangements is essential at the time of cholangiocarcinoma diagnosis to identify patients eligible for targeted therapy in the frontline setting.

✔ The more than twofold improvement in duration of response (14.2 vs. 6.3 months) underscores the depth and durability of benefit achievable with FGFR2-targeted inhibition compared with cytotoxic chemotherapy.

✔ Pemigatinib may offer a chemotherapy-sparing option for patients who are unable to tolerate or who wish to avoid Gem/Cis, based on the magnitude of benefit observed in this biomarker-selected population.

✔ High response rates raise the clinical possibility of downstaging borderline resectable disease, opening a potential avenue for curative-intent surgical intervention in a subset of patients.

✔ Crossover data showing a median PFS of 8.1 months support the continued use of pemigatinib in the second-line setting following chemotherapy progression, consistent with prior FIGHT-202 data.

✔ First-line use of pemigatinib remains investigational and has not yet received FDA approval; regulatory submissions based on these Phase 3 data are anticipated.

Bottom Line

The Phase 3 FIGHT-302 trial provides the first randomized phase 3 evidence supporting pemigatinib as a first-line treatment strategy in patients with FGFR2 fusion- or rearrangement-positive cholangiocarcinoma. With a 42% reduction in the risk of progression or death, a median PFS of 8.3 months, and a median duration of response exceeding 14 months, these results reinforce the transformative potential of precision oncology in this rare but devastating malignancy. Oncology clinicians should prioritize comprehensive biomarker testing at diagnosis to ensure eligible patients have the opportunity to benefit from FGFR2-directed therapy as early as possible in their treatment course.

Sources: